Merck
CN
  • Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.

Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.

International journal of clinical pharmacy (2012-08-10)
Maryam Karimi Khaledi, Katie J Suda, Chasity M Shelton
ABSTRACT

The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.

MATERIALS
Product Number
Brand
Product Description

Supelco
Metoclopramide, VETRANAL®, analytical standard
Supelco
Diphenhydramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Diphenhydramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Diphenhydramine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Diphenhydramine hydrochloride, ≥98% (HPLC)